Clinical context
Myopia studies should distinguish refractive change from axial elongation. The measures are related but not interchangeable, and their clinical meaning depends on age, baseline myopia and follow-up duration. Studies of progression control should also assess tolerability, adherence, rebound after treatment stops and potential adverse effects.
What was studied
This single-center retrospective observational study included 254 eyes of 135 patients with myopia or myopic astigmatism who received a STAAR posterior chamber phakic ICL with a central port between 2013 and 2022. A toric model was used in 226 eyes, or 88.97%. The investigators compared preoperative and postoperative refraction and visual acuity; mean follow-up was 15.05 ± 15.12 months.
How the evidence was produced
A cohort study describes how outcomes are associated with an exposure or treatment in an observed clinical population. This design is useful for routine practice, uncommon events and longer follow-up, but it remains vulnerable to confounding by indication, baseline risk differences and missing data. An association should not automatically be interpreted as a causal effect.
How to interpret the result
The series shows that a central-port ICL can substantially reduce refractive error and provide useful vision in patients with high myopia who may not be suitable for corneal laser correction. The high proportion of toric lenses makes the findings relevant to myopic astigmatism. The study did not compare ICL with LASIK, SMILE, clear-lens extraction or another lens design, however, and cannot establish superiority of one strategy.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
The findings apply most directly to patients who resemble participants in age, baseline refraction and rate of progression. Before selecting an intervention, check durability, the method used to measure axial length, completeness of follow-up and safety. A group average cannot predict the exact response of an individual child or adult.
Limitations
Retrospective data from one center without a control group limit causal inference. Both eyes of some patients were included, requiring statistical handling of within-patient correlation. Follow-up varied widely, and the abstract does not provide detailed outcomes for vault, endothelial cells, pressure, toric rotation, cataract formation or reoperation. Refractive improvement should therefore not be treated as complete evidence of long-term safety; those outcomes require verification in the full text.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.